Jul 27, 2022 04:27 AM

Analysis: How Azvudine Became China’s First Approved Homegrown Covid Pill

(Blue View) — China’s conditional approval Monday of Genuine Biotech’s Azvudine to treat Covid-19 settled months of speculation over what company would win the race to add a homegrown pill to the arsenal for combating the pandemic.

Two months ago, rival Chinese drugmaker Junshi Biosciences published results of a small clinical trial suggesting that its Covid antiviral VV116 might shorten infections. Along with Azvudine, VV116 had expedited clinical trials and registration, underscoring authorities’ support for advancing the drugs’ development.

You've accessed an article available only to subscribers
Share this article
Open WeChat and scan the QR code